| Bonnie Ramsey | CSA: Assistance in Developing and Implementing Clinical Trial Protocols for Treatment of Cystic Fibrosis Using NP101 | N30 Pharmaceuticals, LLC | $10,000 | 01/31/08 |
| Rachel Katzenellenbogen | Regulation of Telomerase by NFX1 | NCI | $134,379 | 01/16/08 |
| Ruth McDonald | EPO Utilization | Market Strategies, Inc. | $15,000 | 01/15/08 |
| Thomas Jones | Bivalirudin (Angiomax) As a Procedural Anticoagulant in the Pediatric Population Undergoing Intravascular Procedures for Congenital Heart Disease | Medicines Company | $63,475 | 01/09/08 |
| Craig Rubens | Early Host: Microbial Interactions in S. aureus Pneumonia | University of Washington | $173,697 | 01/04/08 |